SynthesisFrontiers in medicine2026

The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma: a pooled analysis of four RCTs.

Tonggang Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.